<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to the Learning App!</h1>
        <p id="welcome-description">Explore the following topics to enhance your knowledge.</p>
    </div>
    
    <div class="explanation-card">
        <h1>Introduction to Pregnancy Complications</h1>
        <p>Pregnancy represents a profound physiological adaptation where the maternal body undergoes significant changes to support fetal development. <b>Understanding normal pregnancy physiology is essential to recognize and manage complications</b> when they arise. The uterus expands from about 70g to 1100g at term, with blood flow increasing from 50 mL/min to 500-800 mL/min. The cardiovascular system adapts with increased blood volume (40-50%), cardiac output (30-50%), and decreased systemic vascular resistance.</p>
        
        <p>The <b>placenta</b>, the critical interface between mother and fetus, develops from trophoblastic tissue and is fully formed by 20 weeks. It functions as an endocrine organ (producing hCG, progesterone, estrogen, human placental lactogen), as well as facilitating nutrient/waste exchange. Placental dysfunction underlies many pregnancy complications.</p>
        
        <h2>Epidemiology of Pregnancy Complications</h2>
        <p>Globally, about <b>10-15% of pregnancies</b> experience significant complications. The most common include:</p>
        <ol>
            <li>Hypertensive disorders (5-10% of pregnancies)</li>
            <li>Gestational diabetes (3-9% depending on population)</li>
            <li>Postpartum hemorrhage (1-5%)</li>
            <li>Placental disorders (1-2% for placenta previa)</li>
        </ol>
        
        <p>Risk factors span across <b>maternal age extremes</b> (&lt;18 or &gt;35), <b>pre-existing conditions</b> (hypertension, diabetes), <b>multifetal gestation</b>, and <b>prior obstetric complications</b>. Socioeconomic factors and access to prenatal care significantly impact outcomes.</p>
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which of the following cardiovascular changes is NOT typical in normal pregnancy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Increased cardiac output</li>
            <li data-answer="wrong">Decreased systemic vascular resistance</li>
            <li data-answer="correct">Increased mean arterial pressure</li>
            <li data-answer="wrong">Physiological anemia</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>A 32-year-old primigravida at 28 weeks gestation has a blood pressure of 150/95 mmHg on two occasions 4 hours apart. This is most consistent with:</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Normal pregnancy adaptation</li>
            <li data-answer="correct">Gestational hypertension</li>
            <li data-answer="wrong">Chronic hypertension</li>
            <li data-answer="wrong">White coat hypertension</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>(Pre)Eclampsia: Pathophysiology and Management</h1>
        <p><b>Preeclampsia</b> is a multisystem disorder characterized by new-onset hypertension (≥140/90 mmHg) and proteinuria (≥300 mg/24h) or end-organ dysfunction after 20 weeks gestation. It affects 2-8% of pregnancies globally and remains a leading cause of maternal and perinatal morbidity/mortality.</p>
        
        <h2>Pathophysiology</h2>
        <p>The central pathology involves <b>abnormal placentation</b> leading to reduced uteroplacental perfusion. Incomplete remodeling of spiral arteries results in placental ischemia/hypoxia, releasing anti-angiogenic factors (sFlt-1, soluble endoglin) that cause widespread endothelial dysfunction. This leads to:</p>
        <ol>
            <li><b>Vasoconstriction</b> (hypertension, reduced organ perfusion)</li>
            <li><b>Increased vascular permeability</b> (edema, proteinuria)</li>
            <li><b>Hypercoagulability</b> (microthrombi, HELLP syndrome)</li>
        </ol>
        
        <div class="mnemonic">
            <h4>Mnemonic: "PREECLAMPSIA"</h4>
            <p><b>P</b>roteinuria <b>R</b>enal dysfunction <b>E</b>levated BP <b>E</b>nd-organ damage <b>C</b>NS symptoms <b>L</b>iver enzymes elevated <b>A</b>bnormal placentation <b>M</b>ulti-system <b>P</b>lacental factors <b>S</b>evere outcomes <b>I</b>UGR <b>A</b>ngiogenic imbalance</p>
        </div>
        
        <h2>Clinical Features</h2>
        <p>Preeclampsia can present with a spectrum from mild to life-threatening:</p>
        <ol>
            <li><b>Hypertension</b>: Typically develops after 20 weeks (often 3rd trimester)</li>
            <li><b>Proteinuria</b>: May be absent in 10-15% of cases (non-proteinuric preeclampsia)</li>
            <li><b>Neurological</b>: Headaches, visual changes, hyperreflexia, seizures (eclampsia)</li>
            <li><b>Hepatic</b>: RUQ/epigastric pain, elevated transaminases (may progress to HELLP)</li>
            <li><b>Renal</b>: Oliguria, elevated creatinine, uric acid</li>
            <li><b>Hematologic</b>: Thrombocytopenia, microangiopathic hemolysis</li>
        </ol>
        
        <h2>Diagnosis</h2>
        <p>Diagnosis requires <b>blood pressure criteria</b> (systolic ≥140 or diastolic ≥90 mmHg on two occasions ≥4 hours apart) PLUS either:</p>
        <ol>
            <li>Proteinuria (≥300 mg/24h or protein:creatinine ratio ≥0.3)</li>
            <li>OR evidence of end-organ dysfunction (thrombocytopenia, elevated creatinine, liver enzymes, pulmonary edema, new-onset cerebral/visual symptoms)</li>
        </ol>
        
        <h2>Management</h2>
        <p><b>Definitive treatment is delivery</b>, but timing depends on gestational age and severity:</p>
        <ol>
            <li><b>Mild preeclampsia</b> at ≥37 weeks: Deliver</li>
            <li><b>Mild preeclampsia</b> &lt;37 weeks: Close monitoring, deliver for worsening</li>
            <li><b>Severe preeclampsia</b> at ≥34 weeks: Deliver</li>
            <li><b>Severe preeclampsia</b> &lt;34 weeks: Consider corticosteroids for lung maturity and magnesium sulfate for neuroprotection if continuing pregnancy</li>
        </ol>
        
        <p><b>Magnesium sulfate</b> is the drug of choice for seizure prophylaxis (4-6g IV load then 1-2g/hr maintenance). Antihypertensives (labetalol, nifedipine, hydralazine) are used for severe hypertension (SBP ≥160 or DBP ≥110).</p>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>Which of the following is NOT part of the diagnostic criteria for preeclampsia?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Blood pressure ≥140/90 mmHg after 20 weeks gestation</li>
            <li data-answer="wrong">Proteinuria ≥300 mg/24h</li>
            <li data-answer="correct">Platelet count &lt;50,000/mm³</li>
            <li data-answer="wrong">New-onset cerebral symptoms with hypertension</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>A 29-year-old woman at 32 weeks gestation presents with BP 158/102, 3+ protein on dipstick, and ALT 85 U/L. Which of the following is the most appropriate immediate management?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Oral labetalol and schedule induction at 37 weeks</li>
            <li data-answer="wrong">IV hydralazine and discharge with close follow-up</li>
            <li data-answer="correct">IV magnesium sulfate and prepare for delivery</li>
            <li data-answer="wrong">Observation alone with repeat labs in 1 week</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Gestational Diabetes Mellitus (GDM)</h1>
        <p><b>Gestational diabetes</b> is defined as glucose intolerance first recognized during pregnancy, affecting 3-9% of pregnancies depending on population and diagnostic criteria. It results from the diabetogenic effects of placental hormones (human placental lactogen, progesterone, cortisol) exacerbating underlying insulin resistance.</p>
        
        <h2>Pathophysiology</h2>
        <p>Normal pregnancy induces <b>progressive insulin resistance</b> (up to 50-60% reduction in insulin sensitivity by late pregnancy) to ensure glucose availability for the fetus. In GDM, maternal β-cell compensation is inadequate, leading to:</p>
        <ol>
            <li><b>Maternal hyperglycemia</b>: Especially postprandial hyperglycemia</li>
            <li><b>Fetal hyperinsulinemia</b>: Fetal pancreas responds to maternal glucose crossing placenta</li>
            <li><b>Increased fetal growth</b>: Insulin acts as primary fetal growth hormone</li>
        </ol>
        
        <h2>Screening and Diagnosis</h2>
        <p>Two approaches are commonly used:</p>
        <ol>
            <li><b>One-step (IADPSG)</b>: 75g OGTT at 24-28 weeks, diagnose if any value abnormal:
                <ol>
                    <li>Fasting ≥92 mg/dL</li>
                    <li>1-hour ≥180 mg/dL</li>
                    <li>2-hour ≥153 mg/dL</li>
                </ol>
            </li>
            <li><b>Two-step (ACOG)</b>:
                <ol>
                    <li>50g glucose challenge (non-fasting), 1-hour ≥130-140 mg/dL →</li>
                    <li>100g OGTT, diagnose if ≥2 values abnormal:
                        <ol>
                            <li>Fasting ≥95</li>
                            <li>1-hour ≥180</li>
                            <li>2-hour ≥155</li>
                            <li>3-hour ≥140</li>
                        </ol>
                    </li>
                </ol>
            </li>
        </ol>
        
        <h2>Complications</h2>
        <p>Poorly controlled GDM increases risks for:</p>
        <ol>
            <li><b>Fetal macrosomia</b> (birth weight >4000g): Risk of shoulder dystocia, birth trauma</li>
            <li><b>Neonatal hypoglycemia</b>: Due to fetal hyperinsulinemia after cord clamping</li>
            <li><b>Preterm birth</b>: Often iatrogenic due to complications</li>
            <li><b>Preeclampsia</b>: 2-4 fold increased risk</li>
            <li><b>Future diabetes</b>: 50% risk of developing T2DM within 10 years</li>
        </ol>
        
        <div class="mnemonic">
            <h4>Mnemonic: "SWEET BABY" for GDM complications</h4>
            <p><b>S</b>houlder dystocia <b>W</b>eight gain (excessive) <b>E</b>clampsia <b>E</b>arly delivery <b>T</b>rauma (birth) <b>B</b>ig baby <b>A</b>cidosis (neonatal) <b>B</b>lood sugar issues (neonatal) <b>Y</b>ears later diabetes (maternal)</p>
        </div>
        
        <h2>Management</h2>
        <p>Treatment aims to maintain normoglycemia (fasting &lt;95, 1-hour postprandial &lt;140, 2-hour &lt;120):</p>
        <ol>
            <li><b>Medical nutrition therapy</b>: Carbohydrate-controlled diet (175g/day minimum)</li>
            <li><b>Exercise</b>: Moderate physical activity improves insulin sensitivity</li>
            <li><b>Monitoring</b>: Self-blood glucose monitoring 4x daily (fasting + 1-2h post meals)</li>
            <li><b>Pharmacologic therapy</b> if targets not met in 1-2 weeks:
                <ol>
                    <li><b>Insulin</b> (gold standard): No placental transfer</li>
                    <li><b>Metformin</b>: Crosses placenta but no clear fetal harm</li>
                    <li><b>Glyburide</b>: 2nd line, may increase macrosomia risk</li>
                </ol>
            </li>
        </ol>
        
        <p>Delivery timing is typically 39-40 weeks if well-controlled, earlier if complications arise. Postpartum, 75g OGTT should be performed at 4-12 weeks to assess glucose tolerance.</p>
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>Which of the following is the most appropriate diagnostic threshold for fasting glucose on a 75g OGTT for gestational diabetes?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">≥85 mg/dL</li>
            <li data-answer="correct">≥92 mg/dL</li>
            <li data-answer="wrong">≥100 mg/dL</li>
            <li data-answer="wrong">≥126 mg/dL</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>A 34-year-old woman with GDM at 38 weeks has an estimated fetal weight of 4200g by ultrasound. The most appropriate management is:</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Continue pregnancy until spontaneous labor</li>
            <li data-answer="wrong">Schedule cesarean delivery at 39 weeks</li>
            <li data-answer="correct">Induce labor now given risks of macrosomia</li>
            <li data-answer="wrong">Perform amniocentesis for lung maturity</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Placenta Previa</h1>
        <p><b>Placenta previa</b> occurs when the placenta implants over or near the internal cervical os, affecting approximately 0.3-0.5% of pregnancies at term. The condition classically presents with <b>painless vaginal bleeding</b> in the second or third trimester.</p>
        
        <h2>Classification</h2>
        <p>Four types based on placental relationship to internal os:</p>
        <ol>
            <li><b>Complete previa</b>: Placenta completely covers internal os</li>
            <li><b>Partial previa</b>: Placenta partially covers internal os</li>
            <li><b>Marginal previa</b>: Placental edge reaches margin of internal os</li>
            <li><b>Low-lying placenta</b>: Placenta within 2cm of but not reaching internal os</li>
        </ol>
        
        <p>Early in pregnancy, many placentas appear "low-lying" due to differential growth of the uterus (trophotropism). By term, only ~10% of early findings persist as true previa.</p>
        
        <h2>Risk Factors</h2>
        <p>Factors associated with abnormal placentation:</p>
        <ol>
            <li><b>Prior cesarean delivery</b> (risk increases with number of prior sections)</li>
            <li><b>Multiparity</b></li>
            <li><b>Advanced maternal age</b> (&gt;35 years)</li>
            <li><b>Multiple gestation</b></li>
            <li><b>Smoking</b></li>
            <li><b>Uterine abnormalities</b> (fibroids, prior surgery)</li>
        </ol>
        
        <h2>Clinical Presentation</h2>
        <p>The classic presentation is <b>sudden, painless, bright red vaginal bleeding</b>, often occurring:</p>
        <ol>
            <li>First episode typically in late 2nd or early 3rd trimester</li>
            <li>May be provoked by intercourse or cervical examination</li>
            <li>Bleeding often stops spontaneously but tends to recur</li>
            <li>Uterus typically soft and non-tender</li>
            <li>Fetal status usually normal unless significant maternal hypotension</li>
        </ol>
        
        <div class="mnemonic">
            <h4>Mnemonic: "PREVIA" for placenta previa features</h4>
            <p><b>P</b>ainless bleeding <b>R</b>ed blood <b>E</b>arly 3rd trimester common <b>V</b>aginal delivery contraindicated <b>I</b>nternal os covered <b>A</b>void cervical exam</p>
        </div>
        
        <h2>Diagnosis</h2>
        <p><b>Transvaginal ultrasound</b> is the gold standard (98% accuracy):</p>
        <ol>
            <li>Should be performed if bleeding occurs after 20 weeks</li>
            <li>Transabdominal ultrasound has higher false positive/negative rates</li>
            <li>MRI may be helpful in complex cases (e.g., placenta accreta spectrum)</li>
        </ol>
        
        <p>Digital cervical examination is <b>contraindicated</b> if previa suspected due to risk of provoking hemorrhage.</p>
        
        <h2>Management</h2>
        <p>Depends on gestational age, bleeding severity, and maternal/fetal status:</p>
        <ol>
            <li><b>Asymptomatic previa</b>:
                <ol>
                    <li>Serial ultrasounds to monitor placental location</li>
                    <li>Pelvic rest (no intercourse, avoid cervical exams)</li>
                    <li>Consider corticosteroids if delivery likely before 37 weeks</li>
                </ol>
            </li>
            <li><b>Symptomatic previa</b> (bleeding):
                <ol>
                    <li>Hospitalization for significant bleeding</li>
                    <li>Blood transfusion if hemodynamically unstable</li>
                    <li>Tocolytics may be considered if contractions present (controversial)</li>
                    <li>Delivery if:
                        <ol>
                            <li>Life-threatening hemorrhage</li>
                            <li>Fetal distress</li>
                            <li>Term gestation (37+ weeks)</li>
                        </ol>
                    </li>
                </ol>
            </li>
        </ol>
        
        <p><b>Cesarean delivery</b> is required for complete/partial previa. The optimal timing is typically 36-37 weeks after confirming lung maturity or giving corticosteroids.</p>
    </div>

    <div class="question-card">
        <h1>Question 7</h1>
        <p>A 30-year-old G3P2 at 32 weeks presents with painless bright red vaginal bleeding. Ultrasound shows complete placenta previa. Which of the following is contraindicated?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Transvaginal ultrasound</li>
            <li data-answer="wrong">Cesarean delivery</li>
            <li data-answer="correct">Digital cervical examination</li>
            <li data-answer="wrong">Betamethasone administration</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 8</h1>
        <p>Which of the following is the strongest risk factor for placenta previa?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Primigravida status</li>
            <li data-answer="wrong">Maternal age &lt;25 years</li>
            <li data-answer="correct">Prior cesarean delivery</li>
            <li data-answer="wrong">Gestational diabetes</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Abruptio Placentae</h1>
        <p><b>Placental abruption</b> (abruptio placentae) is the premature separation of a normally implanted placenta from the uterine wall after 20 weeks gestation but before delivery, occurring in 0.4-1% of pregnancies. It is a leading cause of <b>vaginal bleeding in late pregnancy</b> and can result in significant maternal and fetal morbidity.</p>
        
        <h2>Pathophysiology</h2>
        <p>The primary event is <b>hemorrhage into the decidua basalis</b>, leading to separation of the placenta from the uterine wall. This can result from:</p>
        <ol>
            <li><b>Vascular disruption</b>: Chronic hypertension, preeclampsia, cocaine use</li>
            <li><b>Mechanical factors</b>: Trauma, rapid uterine decompression (ROM in polyhydramnios)</li>
            <li><b>Thrombophilia</b>: Inherited or acquired hypercoagulable states</li>
        </ol>
        
        <p>Bleeding may be <b>revealed</b> (external via cervix) or <b>concealed</b> (retroplacental, more dangerous). Severe cases can lead to <b>Couvelaire uterus</b> (blood infiltrating myometrium) and <b>disseminated intravascular coagulation (DIC)</b>.</p>
        
        <h2>Risk Factors</h2>
        <p>Major risk factors include:</p>
        <ol>
            <li><b>Hypertensive disorders</b> (most significant risk factor)</li>
            <li><b>Prior abruption</b> (recurrence risk 5-17%)</li>
            <li><b>Trauma</b> (motor vehicle accidents, domestic violence)</li>
            <li><b>Smoking</b> (2.5x increased risk)</li>
            <li><b>Cocaine use</b> (vasospasm)</li>
            <li><b>PPROM</b> (especially with infection)</li>
            <li><b>Thrombophilias</b> (Factor V Leiden, antiphospholipid syndrome)</li>
        </ol>
        
        <h2>Clinical Presentation</h2>
        <p>The classic triad is <b>vaginal bleeding, uterine tenderness, and fetal distress</b>, though presentation varies:</p>
        <ol>
            <li><b>Bleeding</b>: May be absent in concealed abruption (20% cases)</li>
            <li><b>Uterine hypertonus</b>: "Woody" consistency, tetanic contractions</li>
            <li><b>Abdominal pain</b>: Sudden onset, constant (not intermittent like labor)</li>
            <li><b>Fetal distress</b>: Late decelerations, bradycardia, or demise</li>
            <li><b>Maternal shock</b>: Out of proportion to visible blood loss in concealed abruption</li>
        </ol>
        
        <div class="mnemonic">
            <h4>Mnemonic: "ABRUPTIO" for placental abruption features</h4>
            <p><b>A</b>bdominal pain <b>B</b>leeding (may be concealed) <b>R</b>igid uterus <b>U</b>terine tenderness <b>P</b>reterm labor <b>T</b>rauma/HTN risk factors <b>I</b>UFD risk <b>O</b>utcome poor if severe</p>
        </div>
        
        <h2>Diagnosis</h2>
        <p>Primarily a <b>clinical diagnosis</b> with supporting evidence from:</p>
        <ol>
            <li><b>Ultrasound</b>: Sensitivity only 25% for detection (retroplacental clot may be seen)</li>
            <li><b>Laboratory tests</b>:
                <ol>
                    <li>Decreased fibrinogen (often &lt;200 mg/dL in severe cases)</li>
                    <li>Elevated D-dimer</li>
                    <li>Thrombocytopenia</li>
                    <li>Prolonged PT/PTT in DIC</li>
                </ol>
            </li>
            <li><b>Fetal monitoring</b>: Non-reassuring patterns common</li>
        </ol>
        
        <h2>Management</h2>
        <p>Depends on gestational age and severity:</p>
        <ol>
            <li><b>Immediate delivery</b> indicated for:
                <ol>
                    <li>Severe abruption with fetal distress (category II/III tracing)</li>
                    <li>Maternal hemodynamic instability</li>
                    <li>Term gestation (≥37 weeks)</li>
                </ol>
            </li>
            <li><b>Vaginal delivery</b> preferred if mother and fetus stable</li>
            <li><b>Cesarean delivery</b> if:
                <ol>
                    <li>Fetal distress with viable fetus</li>
                    <li>Maternal indications (severe hemorrhage, DIC)</li>
                </ol>
            </li>
            <li><b>Expectant management</b> may be considered for:
                <ol>
                    <li>Mild abruption at &lt;34 weeks with stable maternal/fetal status</li>
                    <li>Administer corticosteroids for fetal lung maturity</li>
                </ol>
            </li>
        </ol>
        
        <p><b>Supportive care</b> includes IV fluids, blood transfusion if needed, and monitoring for DIC. Rhogam should be given to Rh-negative women.</p>
    </div>

    <div class="question-card">
        <h1>Question 9</h1>
        <p>Which of the following is the most characteristic feature of placental abruption?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Painless vaginal bleeding</li>
            <li data-answer="correct">Painful rigid uterus</li>
            <li data-answer="wrong">Absent fetal heart tones at diagnosis</li>
            <li data-answer="wrong">Low-lying placenta on ultrasound</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 10</h1>
        <p>A 28-year-old woman at 35 weeks presents with severe abdominal pain and vaginal bleeding. BP is 85/50, HR 120, uterus is rigid and tender. Fetal heart rate shows bradycardia at 80 bpm. The most likely diagnosis is:</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Placenta previa</li>
            <li data-answer="correct">Placental abruption</li>
            <li data-answer="wrong">Uterine rupture</li>
            <li data-answer="wrong">Round ligament pain</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Postpartum Hemorrhage (PPH)</h1>
        <p><b>Postpartum hemorrhage</b> is defined as blood loss ≥500 mL after vaginal delivery or ≥1000 mL after cesarean, or any amount causing hemodynamic instability. It is the <b>leading cause of maternal mortality worldwide</b>, accounting for 25% of maternal deaths.</p>
        
        <h2>Classification</h2>
        <p>PPH can be categorized by timing and etiology:</p>
        <ol>
            <li><b>Primary (early) PPH</b>: Within 24 hours of delivery (most common)</li>
            <li><b>Secondary (late) PPH</b>: 24 hours to 12 weeks postpartum</li>
        </ol>
        
        <p>The "4 T's" mnemonic organizes major causes:</p>
        <ol>
            <li><b>Tone</b>: Uterine atony (70% of cases)</li>
            <li><b>Trauma</b>: Genital tract lacerations, hematomas</li>
            <li><b>Tissue</b>: Retained placenta, clots</li>
            <li><b>Thrombin</b>: Coagulopathy (inherited or acquired)</li>
        </ol>
        
        <h2>Risk Factors</h2>
        <p>Antepartum and intrapartum factors increase PPH risk:</p>
        <ol>
            <li><b>Uterine overdistension</b> (multiple gestation, polyhydramnios, macrosomia)</li>
            <li><b>Prolonged labor</b> (especially 3rd stage &gt;30 minutes)</li>
            <li><b>Chorioamnionitis</b></li>
            <li><b>Placental abnormalities</b> (previa, accreta, abruption)</li>
            <li><b>Coagulopathy</b> (preeclampsia, HELLP, inherited disorders)</li>
            <li><b>Medications</b> (magnesium sulfate, tocolytics)</li>
        </ol>
        
        <h2>Clinical Presentation</h2>
        <p>Signs vary by etiology but may include:</p>
        <ol>
            <li><b>Excessive bleeding</b>: Soaking &gt;1 pad/hour, blood pooling</li>
            <li><b>Signs of shock</b>: Tachycardia, hypotension, pallor, oliguria</li>
            <li><b>Boggy uterus</b> (with atony) or firm uterus with continued bleeding (trauma)</li>
            <li><b>Perineal/vaginal hematoma</b> (with trauma)</li>
        </ol>
        
        <div class="mnemonic">
            <h4>Mnemonic: "HEMORRHAGE" for PPH management steps</h4>
            <p><b>H</b>elp (activate team) <b>E</b>stimate blood loss <b>M</b>assage uterus <b>O</b>xytocin <b>R</b>emove clots <b>R</b>epair lacerations <b>H</b>emodynamic support <b>A</b>dvanced measures (tamponade, surgery) <b>G</b>ive blood products <b>E</b>nsure monitoring</p>
        </div>
        
        <h2>Management</h2>
        <p>Treatment follows a stepwise approach:</p>
        <ol>
            <li><b>Initial measures</b>:
                <ol>
                    <li>Call for help (activate massive transfusion protocol if needed)</li>
                    <li>Bimanual uterine massage</li>
                    <li>Oxytocin (first-line, 40 units in 1L NS at 200 mL/hr)</li>
                    <li>Examine for/repair lacerations</li>
                </ol>
            </li>
            <li><b>Second-line uterotonics</b> if bleeding continues:
                <ol>
                    <li>Methylergonovine (0.2mg IM, contraindicated in HTN)</li>
                    <li>Carboprost (Hemabate, 250mcg IM, avoid in asthma)</li>
                    <li>Misoprostol (800mcg PR)</li>
                </ol>
            </li>
            <li><b>Mechanical/surgical interventions</b>:
                <ol>
                    <li>Uterine tamponade (Bakri balloon, packing)</li>
                    <li>Uterine artery embolization</li>
                    <li>Compression sutures (B-Lynch)</li>
                    <li>Hysterectomy (last resort)</li>
                </ol>
            </li>
            <li><b>Resuscitation</b>:
                <ol>
                    <li>Two large-bore IVs, crystalloids</li>
                    <li>Blood products (PRBC:FFP:platelets in 1:1:1 ratio for massive transfusion)</li>
                    <li>Monitor for coagulopathy (check fibrinogen, platelets)</li>
                </ol>
            </li>
        </ol>
        
        <p><b>Secondary PPH</b> is often due to retained products or infection, requiring ultrasound evaluation, antibiotics, and possible dilation & curettage.</p>
    </div>

    <div class="question-card">
        <h1>Question 11</h1>
        <p>What is the cut-off for "primary" vs "secondary" PPH?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">12 hr</li>
            <li data-answer="correct">24 hr</li>
            <li data-answer="wrong">2 days</li>
            <li data-answer="wrong">1 week</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 12</h1>
        <p>What is the most likely cause of PPH?</p>
        <ul class="options" id="options">
            <li data-answer="correct">Tone</li>
            <li data-answer="wrong">Trauma</li>
            <li data-answer="wrong">Thrombin</li>
            <li data-answer="wrong">Tissue</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 13</h1>
        <p>Both oxytocin and misoprostol are given in case of PPH. Which comes when?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Oxytocin primary, misoprostol primary</li>
            <li data-answer="correct">Oxytocin primary, misoprostol secondary</li>
            <li data-answer="wrong">Oxytocin secondary, misoprostol primary</li>
            <li data-answer="wrong">Oxytocin secondary, misoprostol secondary</li>
        </ul>
    </div>

    <div class="placeholder" id="empty">Test</div>

</div>